Biomerica's test targets cancer and osteoporosis:
This article was originally published in Clinica
Executive Summary
Biomerica reports that it is launching a blood test for the hormone calcitonin, which can be used as a means of diagnosing cancer of the thyroid and as an adjunct for monitoring osteoporosis (bone loss). Calcitonin is produced in the thyroid gland that helps regulate blood calcium, says the Newport Beach, California firm, which plans to release the test in the US and in Europe.